Skip to main content

Angeles Alvarez Secord, MD

Angeles Secord, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Education and Training

  • Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
  • M.D., University of Washington, 1994


  • Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011


Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment. 



Kokosis, G, Schmitz, R, Secord, AA, Havrilesky, LJ, Berchuck, A, Mantyh, CR, and Erdmann, D. "A modified bipedicle VRAM flap for simultaneous reconstruction of a perineal and posterior vaginal defect." Gynakologe 47, no. 10 (January 1, 2014): 784-787.

Full Text

Herzog, TJ, Monk, BJ, Rose, PG, Braly, P, Hines, JF, Bell, MC, Wenham, RM, Secord, AA, Roman, LD, Einstein, MH, Drake, RD, and Childs, BH. "A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube." Gynecologic Oncology 132, no. 3 (January 1, 2014): 517-525.

Full Text

Previs, RA, Bevis, KS, Huh, W, Tillmanns, T, Perry, L, Moore, K, Chapman, J, McClung, C, Kiet, T, Java, J, Chan, J, and Secord, AA. "A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy." Gynecologic Oncology 132, no. 3 (January 1, 2014): 531-536.

Full Text

Previs, RA, Edwards, JM, Secord, AA, Nucci, MR, Bentley, RC, and Hall, AHS. "Cystic fibrosis involving the cervix, mimicking a well-differentiated adenocarcinoma: A case report." International Journal of Gynecological Pathology 33, no. 1 (January 1, 2014): 100-104.

Full Text

Lopez-Acevedo, M, Grace, L, Teoh, D, Whitaker, R, Adams, DJ, Jia, J, Nixon, AB, and Secord, AA. "Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines." Gynecologic oncology research and practice 1 (January 2014): 2-.

Full Text

Davidson, BA, Rubatt, JM, Corcoran, DL, Teoh, DK, Bernardini, MQ, Grace, LA, Soper, WJ, Berchuck, A, Siamakpour-Reihani, S, Chen, W, Owzar, K, Murphy, SK, and Secord, AA. "Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines." Frontiers in Oncology 4 (January 2014): 163-.

Full Text

Havrilesky, LJ, Secord, AA, Ehrisman, JA, Berchuck, A, Valea, FA, Lee, PS, Gaillard, SL, Samsa, GP, Cella, D, Weinfurt, KP, Abernethy, AP, and Reed, SD. "Patient preferences in advanced or recurrent ovarian cancer." Cancer 120, no. 23 (January 1, 2014): 3651-3659.

Full Text

Davidson, BA, and Secord, AA. "Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer." International Journal of Women'S Health 6 (January 2014): 289-300. (Review)

Full Text

Herzog, TJ, Alvarez, RD, Secord, A, Goff, BA, Mannel, RS, Monk, BJ, and Coleman, RL. "SGO guidance document for clinical trial designs in ovarian cancer: A changing paradigm." Gynecologic Oncology 135, no. 1 (2014): 3-7.

Full Text

Lee, PS, and Secord, AA. "Targeting molecular pathways in endometrial cancer: A focus on the FGFR pathway." Cancer Treatment Reviews 40, no. 4 (2014): 507-512.